Why Vera Therapeutics Is Rising In Pre-market?

(RTTNews) - Vera Therapeutics (VERA) announced the atacicept Biologics License Application for the treatment of adults with immunoglobulin A nephropathy was accepted for Priority Review by the FDA. The BLA, which was submitted using the Accelerated Approval Program, was assigned a PDUFA target action date of July 7, 2026.

Marshall Fordyce, Founder and CEO of Vera Therapeutics, said: "FDA's Priority Review designation reinforces the need for new therapies that can reshape the IgAN treatment landscape. We remain committed to working with the FDA to facilitate a thorough review of the BLA."

In pre-market trading on NasdaqGM, Vera Therapeutics shares are up 23.8 percent to $57.59.

For More Such Health News, visit rttnews.com.